Drug and Therapeutics Bulletin 2001;39:17-21; doi:10.1136/dtb.2001.39317
Copyright © 2001 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Statin therapy - what now?

Relevant BNF section: 2.12

In England, only 30% of patients with established coronary heart disease (CHD) and raised serum lipids, and fewer than 4% of individuals eligible for primary prevention, receive lipid-lowering therapy.1 Target total cholesterol concentrations are achieved in fewer than 50% of patients who do receive such treatment.1 Here, we review the use of statin therapy in the prevention of CHD events.




This article has been cited by other articles:


Home page
 HeartHome page
P H Whincup, J R Emberson, L Lennon, M Walker, O Papacosta, and A Thomson
Low prevalence of lipid lowering drug use in older men with established coronary heart disease
Heart, July 1, 2002; 88(1): 25 - 29.
[Abstract] [Full Text] [PDF]


About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 2001 BMJ Publishing Group Ltd.